AstraZeneca Crestor Myopathy Seen At Lower Doses; EU Label Approved

AstraZeneca's Crestor myopathy incidence in 40 mg and lower is less than .01%, Cardiovascular Therapy Head Hamish Cameron, MD, said during the company's annual business review Nov. 7